These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 3949092)

  • 21. A randomised, double-blind, sham-controlled study of granulocyte/monocyte apheresis for moderate to severe Crohn's disease.
    Sands BE; Katz S; Wolf DC; Feagan BG; Wang T; Gustofson LM; Wong C; Vandervoort MK; Hanauer S
    Gut; 2013 Sep; 62(9):1288-94. PubMed ID: 22760005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Value of indium-111 granulocyte scintigraphy in the assessment of Crohn's disease of the small intestine: prospective investigation.
    Crama-Bohbouth GE; Arndt JW; Peña AS; Verspaget HW; Tjon A Tham RT; Weterman IT; Pauwels EK; Lamers CB
    Digestion; 1988; 40(4):227-36. PubMed ID: 3234629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Faecal diversion for Crohn's colitis: a model to study the role of the faecal stream in the inflammatory process.
    Winslet MC; Allan A; Poxon V; Youngs D; Keighley MR
    Gut; 1994 Feb; 35(2):236-42. PubMed ID: 8307475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome.
    Kaiser T; Langhorst J; Wittkowski H; Becker K; Friedrich AW; Rueffer A; Dobos GJ; Roth J; Foell D
    Gut; 2007 Dec; 56(12):1706-13. PubMed ID: 17675327
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Specificity of indium-111 granulocyte scanning and fecal excretion measurement in inflammatory bowel disease--an autoradiographic study.
    Keshavarzian A; Price YE; Peters AM; Lavender JP; Wright NA; Hodgson HJ
    Dig Dis Sci; 1985 Dec; 30(12):1156-60. PubMed ID: 4064866
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Granulocytapheresis in steroid-dependent and steroid-resistant patients with inflammatory bowel disease: a prospective observational study.
    Sacco R; Romano A; Mazzoni A; Bertini M; Federici G; Metrangolo S; Parisi G; Nencini C; Giampietro C; Bertoni M; Tumino E; Scatena F; Bresci G
    J Crohns Colitis; 2013 Dec; 7(12):e692-7. PubMed ID: 23870727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Faecal lactoferrin, capsule endoscopy and Crohn's disease. Is there a three way relationship? A pilot study.
    Sidhu R; Sanders DS; Wilson P; Foye L; Morley S; McAlindon ME
    J Gastrointestin Liver Dis; 2010 Sep; 19(3):257-60. PubMed ID: 20922188
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery.
    Wright EK; Kamm MA; De Cruz P; Hamilton AL; Ritchie KJ; Krejany EO; Leach S; Gorelik A; Liew D; Prideaux L; Lawrance IC; Andrews JM; Bampton PA; Jakobovits SL; Florin TH; Gibson PR; Debinski H; Macrae FA; Samuel D; Kronborg I; Radford-Smith G; Selby W; Johnston MJ; Woods R; Elliott PR; Bell SJ; Brown SJ; Connell WR; Day AS; Desmond PV; Gearry RB
    Gastroenterology; 2015 May; 148(5):938-947.e1. PubMed ID: 25620670
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An open-label prospective randomized multicenter study of intensive versus weekly granulocyte and monocyte apheresis in active crohn's disease.
    Yoshimura N; Yokoyama Y; Matsuoka K; Takahashi H; Iwakiri R; Yamamoto T; Nakagawa T; Fukuchi T; Motoya S; Kunisaki R; Kato S; Hirai F; Ishiguro Y; Tanida S; Hiraoka S; Mitsuyama K; Ishihara S; Tanaka S; Otaka M; Osada T; Kagaya T; Suzuki Y; Nakase H; Hanai H; Watanabe K; Kashiwagi N; Hibi T
    BMC Gastroenterol; 2015 Nov; 15():163. PubMed ID: 26585569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trichuris suis therapy in Crohn's disease.
    Summers RW; Elliott DE; Urban JF; Thompson R; Weinstock JV
    Gut; 2005 Jan; 54(1):87-90. PubMed ID: 15591509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Remission maintained by monotherapy after biological + immunosuppressive combination for Crohn's disease in clinical practice.
    Ampuero J; Rojas-Feria M; Castro-Fernández M; Millán-Lorenzo M; Guerrero-Jiménez P; Romero-Gómez M
    J Gastroenterol Hepatol; 2016 Jan; 31(1):112-8. PubMed ID: 26173493
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inflammation-driven malnutrition: a new screening tool predicts outcome in Crohn's disease.
    Jansen I; Prager M; Valentini L; Büning C
    Br J Nutr; 2016 Sep; 116(6):1061-7. PubMed ID: 27546478
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Faecal calprotectin: a new marker for Crohn's disease?
    Wassell J; Dolwani S; Metzner M; Losty H; Hawthorne A
    Ann Clin Biochem; 2004 May; 41(Pt 3):230-2. PubMed ID: 15117438
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy.
    Forbes GM; Sturm MJ; Leong RW; Sparrow MP; Segarajasingam D; Cummins AG; Phillips M; Herrmann RP
    Clin Gastroenterol Hepatol; 2014 Jan; 12(1):64-71. PubMed ID: 23872668
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fecal radioiodide excretion following intravenous injection of 131-I-albumin and 125-I-immunoglobulin G in chronic inflammatory bowel disease. An aid to topographic diagnosis.
    Jarnum S; Jensen KB
    Gastroenterology; 1975 Jun; 68(6):1433-44. PubMed ID: 1132626
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Faecal calprotectin in the assessment of Crohn's disease activity.
    Gaya DR; Lyon TD; Duncan A; Neilly JB; Han S; Howell J; Liddell C; Stanley AJ; Morris AJ; Mackenzie JF
    QJM; 2005 Jun; 98(6):435-41. PubMed ID: 15879440
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum calprotectin as a biomarker for Crohn's disease.
    Meuwis MA; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Piver E; Seidel L; Colombel JF; Louis E;
    J Crohns Colitis; 2013 Dec; 7(12):e678-83. PubMed ID: 23845231
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn's disease.
    Cassinotti A; Annaloro C; Ardizzone S; Onida F; Della Volpe A; Clerici M; Usardi P; Greco S; Maconi G; Porro GB; Deliliers GL
    Gut; 2008 Feb; 57(2):211-7. PubMed ID: 17895357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Value of C-reactive protein in the evaluation of activity in ulcerative colitis and Crohn's disease].
    Vucelić B; Krznarić Z; Sentić M; Milicić D; Korać B; Cvorisćec D; Stavljenić A
    Lijec Vjesn; 1990; 112(9-10):281-4. PubMed ID: 2093781
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Urinary zinc excretion in Crohn's disease.
    Pironi L; Miglioli M; Cornia GL; Ursitti MA; Tolomelli M; Piazzi S; Barbara L
    Dig Dis Sci; 1987 Apr; 32(4):358-62. PubMed ID: 3829879
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.